Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA.

Future oncology (London, England) - 1 May 2020

Zhang Jinling, Zhang Xueli, Shen Shuwei

Abstract excerpt

Aim: Circulating tumor DNA is promising for routine monitoring of breast cancer. Noninvasive testing allows regular probing using plasma and urine samples. Methods: Peripheral blood and simultaneous urine collection from patients were quantified. Concordance between methods were made. Serial time-point measurements were correlated to disease outcome. Results: Index measurements demonstrate over 90% concordance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Circulating Tumor DNA

Share to DNA, Neoplasm

Share to Neoplasm Recurrence, Local

Share to Plasma

Source

Identifiers

PMID: 32270709
DOI: 10.2217/fon-2020-0074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA.PMID 32270709Read ↗

Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA.Semantic proximity Read ↗

Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.Semantic proximity Read ↗

Breast cancer: Tracking ctDNA to evaluate relapse risk.Semantic proximity Read ↗

Does molecular monitoring matter in early-stage breast cancer?Semantic proximity Read ↗

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer.Semantic proximity Read ↗

Hematologic Biomarkers and AI in Breast Cancer: A New Frontier for Risk Stratification and Treatment Response PredictionSemantic proximity Read ↗

Circulating DNA as biomarker in breast cancer.Semantic proximity Read ↗

Hematologic Biomarkers and AI in Breast Cancer: A New Frontier for Risk Stratification and Treatment Response PredictionSemantic proximity Read ↗

Diagnostic relevance of plasma DNA and DNA integrity for breast cancerSemantic proximity Read ↗

A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 YearsSemantic proximity Read ↗

Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patientsSemantic proximity Read ↗

Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.